C
Chrystal U. Louis
Researcher at Baylor College of Medicine
Publications - 39
Citations - 4801
Chrystal U. Louis is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 18, co-authored 37 publications receiving 3840 citations. Previous affiliations of Chrystal U. Louis include Houston Methodist Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee,Rebecca Gardner,David L. Porter,Chrystal U. Louis,Nabil Ahmed,Michael C. Jensen,Stephan A. Grupp,Stephan A. Grupp,Crystal L. Mackall +8 more
TL;DR: A novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of C RS based on severity is presented, to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of the syndrome.
Journal ArticleDOI
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis,Chrystal U. Louis,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti,Martin Pule,Eric Yvon,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Oumar Diouf,Oumar Diouf,Enli Liu,Hao Liu,Meng Fen Wu,Adrian P. Gee,Zhuyong Mei,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +23 more
TL;DR: It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.
Journal ArticleDOI
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Andras Heczey,Chrystal U. Louis,Barbara Savoldo,Olga Dakhova,April G. Durett,Bambi Grilley,Hao Liu,Mengfeng F. Wu,Zhuyong Mei,Adrian P. Gee,Birju Mehta,Huimin Zhang,Nadia Mahmood,Haruko Tashiro,Helen E. Heslop,Gianpietro Dotti,Cliona M. Rooney,Malcolm K. Brenner +17 more
TL;DR: CARTs are safe, and Cy/Flu can further increase their expansion, which may have contributed to the modest early antitumor responses; the effect of these cells merits further study.
Journal ArticleDOI
Neuroblastoma: Molecular Pathogenesis and Therapy
TL;DR: Systematic classification of patients coupled with therapeutic advances point to a future of improved clinical outcomes for this biologically distinct and highly aggressive pediatric malignancy.
Journal ArticleDOI
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Chrystal U. Louis,Karin Straathof,Karin Straathof,Catherine M. Bollard,Catherine M. Bollard,Sravya Ennamuri,Sravya Ennamuri,Claudia Gerken,Claudia Gerken,Teresita Lopez,Teresita Lopez,M. Helen Huls,M. Helen Huls,Andrea M. Sheehan,Meng Fen Wu,Hao Liu,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop,Stephen Gottschalk,Stephen Gottschalk +22 more
TL;DR: Treatment of patients with relapsed/refractory EBV-positive NPC withEBV-CTLs is safe and can be associated with significant, long-term clinical benefit, particularly for patients with locoregional disease.